Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Not for human consumption or medical use
Tirzepatide for MASH with fibrosis 15 mg produced a large majority disease-resolution rate versus a small placebo rate: Loomba NEJM 2024 (SYNERGY-NASH)
On top of that, unregulated dosing and contamination can harm performance and health
This compound is a modified form of BPC-157, meticulously formulated for research purposes
GHK-Cu compounds with consistency
For the bigger picture on where GHK-Cu fits, read our peptide therapy guide and the rising popularity of peptide therapy in India
US$ 27.70
US$ 27.72
US$ 20.63
